Skip to main content

Table 4 Clinicopathological parameters related to tumor recurrence

From: Prognostic significance of stem cell/ epithelial-mesenchymal transition markers in periampullary/pancreatic cancers: FGFR1 is a promising prognostic marker

Clinicopathologic parametersNo. (%)P value
Non-recurrence (N = 58)Recurrence (N = 61)
Age (yrs)62.4 ± 9.964.4 ± 8.90.258
Sex
 Male37 (63.8%)36 (59.0%)0.729
 Female21 (36.2%)25 (41.0%) 
Original location (epicenter)  0.347
 Periampullary duodenum2 (3.4%)1 (1.6%) 
 AOV20 (34.5%)16 (26.2%) 
 Pancreatic head15 (25.9%)16 (26.2%) 
 Distal CBD19 (32.8%)28 (45.9%) 
 Proximal CBD2 (3.4%)0 (0.0%) 
Revised location (epicenter)  NA
 AOV0 (0.0%)0 (0.0%) 
 Pancreatic head20 (34.5%)14 (23.0%) 
 Distal CBD38 (65.5%)47 (77.0%) 
Combined location (epicenter)  NA
 AOV0 (0.0%)0 (0.0%) 
 Pancreatic head17 (34.7%)13 (26.5%) 
 Distal CBD32 (65.3%)36 (73.5%) 
Original T stage  0.536
 Tis1 (1.7%)0 (0.0%) 
 T113 (22.4%)8 (13.1%) 
 T214 (24.1%)15 (24.6%) 
 T328 (48.3%)35 (57.4%) 
 T42 (3.4%)3 (4.9%) 
Gross type  NA
 Fungating12 (21.4%)8 (13.3%) 
 Infiltrative37 (66.1%)50 (83.3%) 
 Ulcerofungating2 (3.6%)1 (1.7%) 
 Sessile3 (5.4%)1 (1.7%) 
 Solid2 (3.6%)0 (0.0%) 
Ulcer
 Absent54 (93.1%)55 (90.2%)0.805
 Present4 (6.9%)6 (9.8%) 
Average tumor size3.0 ± 1.53.3 ± 1.70.199
Tumor size < 4.5 cm47 (81.0%)44 (72.1%)0.353
  ≥ 4.5 cm11 (19.0%)17 (27.9%) 
Radial resection margin Absent56 (96.6%)57 (93.4%)0.722
 Present2 (3.4%)4 (6.6%) 
No. of positive lymph nodes0.7 ± 1.21.2 ± 1.80.073
No. of dissected lymph nodes11.6 ± 7.411.2 ± 7.00.730
N stage
 N038 (65.5%)34 (55.7%)0.366
 N120 (34.5%)27 (44.3%) 
M stage
 M055 (94.8%)60 (98.4%)0.575
 M13 (5.2%)1 (1.6%) 
Lymphatic invasion Absent38 (65.5%)30 (49.2%)0.106
 Present20 (34.5%)31 (50.8%) 
Vascular invasion
 Absent51 (87.9%)53 (86.9%)1.000
 Present7 (12.1%)8 (13.1%) 
Perineural invasion Absent27 (46.6%)26 (42.6%)0.805
 Present31 (53.4%)35 (57.4%) 
Histologic grade  0.845
 Well differentiated17 (29.3%)17 (27.9%) 
 Moderately differentiated37 (63.8%)38 (62.3%) 
 Poorly differentiated4 (6.9%)6 (9.8%) 
Degree of fibrosis  0.020*
 None4 (6.9%)0 (0.0%) 
 Mild11 (19.0%)9 (14.8%) 
 Moderate36 (62.1%)33 (54.1%) 
 Severe7 (12.1%)19 (31.1%) 
Degree of inflammation  0.415
 Mild21 (36.2%)28 (45.9%) 
 Moderate30 (51.7%)29 (47.5%) 
 Severe7 (12.1%)4 (6.6%) 
Histologic subtype  0.932
 Pancreaticobiliary subtype8 (14.0%)21 (34.4%) 
 Prone to pancreaticobiliary subtype29 (50.9%)28 (45.9%) 
 Prone to intestinal subtype10 (17.5%)8 (13.1%) 
 Intestinal subtype10 (17.5%)4 (6.6%) 
CK7
 Negative8 (13.8%)2 (3.3%)0.145
 1+5 (8.6%)5 (8.2%) 
 2+10 (17.2%)17 (27.9%) 
 3+35 (60.3%)37 (60.7%) 
CK20
 Negative28 (48.3%)42 (68.9%)0.110
 1+15 (25.9%)7 (11.5%) 
 2+8 (13.8%)7 (11.5%) 
 3+7 (12.1%)5 (8.2%) 
CDX
 Negative13 (22.4%)21 (34.4%)0.086
 1+18 (31.0%)23 (37.7%) 
 2+10 (17.2%)10 (16.4%) 
 3+17 (29.3%)7 (11.5%) 
MUC
 Negative51 (87.9%)56 (91.8%)0.692
 Positive7 (12.1%)5 (8.2%) 
SOX2 (nuclear) Negative5 (8.6%)6 (9.8%)0.497
 1+31 (53.4%)31 (50.8%) 
 2+20 (34.5%)24 (39.3%) 
 3+2 (3.4%)0 (0.0%) 
SOX2 (cytoplasmic) Negative30 (51.7%)32 (52.5%)0.107
 1+24 (41.4%)29 (47.5%) 
 2+4 (6.9%)0 (0.0%) 
CD24
 Negative4 (6.9%)2 (3.3%)0.728
 1+37 (63.8%)37 (60.7%) 
 2+15 (25.9%)20 (32.8%) 
 3+2 (3.4%)2 (3.3%) 
OCT4
 1+12 (20.7%)14 (23.0%)0.943
 2+34 (58.6%)34 (55.7%) 
 3+12 (20.7%)13 (21.3%) 
IGF-1
 Negative7 (12.1%)6 (9.8%)0.778
 1+32 (55.2%)38 (62.3%) 
 2+16 (27.6%)14 (23.0%) 
 3+3 (5.2%)3 (4.9%) 
FGFR
 1+3 (5.2%)4 (6.6%)0.697
 2+22 (37.9%)27 (44.3%) 
 3+33 (56.9%)30 (49.2%) 
VEGF
 1+6 (10.3%)10 (17.2%)0.547
 2+38 (65.5%)36 (62.1%) 
 3+14 (24.1%)12 (20.7%) 
CD44v6 Negative6 (10.3%)6 (9.8%)0.927
 1+18 (31.0%)22 (36.1%) 
 2+21 (36.2%)19 (31.1%) 
 3+13 (22.4%)14 (23.0%)